ArticleJPGN reports2026
Gastrointestinal manifestations following chimeric antigen receptor T-cell (CAR-T) 19 therapy in pediatric patients with CD19+ acute lymphoblastic leukemia.
Article in JPGN reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric patients with CD19+ acute lymphoblastic leukemia (ALL) undergoing chimeric antigen receptor T-cell (CAR-T) therapy frequently experience gastrointestinal (GI) complications. A retrospective study analyzed 13 patients (median age: 8 years) treated between January 2020 and January 2024. Seventy percent of patients experienced symptoms such as diarrhea (46%), abdominal pain (30%), and nausea/vomiting (38%). Despite adequate nutritional tolerance in 70% of cases, 31% required parenteral nutrition. Chronic malnutrition prevalence increased from 23% at baseline to 30% 6 months after therapy. These findings highlight the significant impact of CAR-T therapy on GI health and nutritional status in pediatric patients. The high incidence of GI side effects and the associated nutritional challenges underline the importance of implementing multidisciplinary care and close monitoring to mitigate these complications. Optimizing nutritional management could improve patient outcomes and inform strategies for future treatments in this vulnerable population. Further research is needed to refine supportive care approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.